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Abstract: This paper reports on the modification of two synthetic steps in the usual protocol used
for obtaining EMICORON. EMICORON is a benzo[ghi]perylen-diimide, which was synthesized
for the first time in our laboratory in 2012, and has shown to have in vivo antitumor activities
that interferes with the tumor growth and development using a multi-target mechanism of action.
The provided modifications, which involved the reaction times, the reaction conditions, and the
work-up procedures, allowed the global yield of the process to be increased from 28% to about 40%.
Thus, this new procedure may be more suitable for recovering higher amounts of EMICORON to be
used in further preclinical studies.
Keywords: EMICORON; polycyclic aromatic compounds; organic synthesis; synthesis
improvements; anticancer activity
1. Introduction
Polycyclic aromatic compounds with hydrophilic polar side chains are well known to
inhibit telomerase [1] and therefore possess anticancer properties [2,3]. In particular, perylene
and coronene [4,5] derivatives with further modifications have shown to be highly selective,
with good activity.
EMICORON represents another development of the above-mentioned compounds. It is a
polyaromatic compound constituted by a benzo[ghi]perylenic core that presents two ethyl-piperidine
chains on the major axis, together with one ethyl-piperidine chain and one piperidine chain on the
minor axis (Figure 1) [6].
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1. Introduction 
Polycyclic aromatic compounds with hydrophilic polar side chains are well known to inhibit 
telomerase [1] and therefore possess anticancer properties [2,3]. In particular, perylene and coronene 
[4,5] derivatives with further modifications have shown to be highly selective, with good activity. 
EMICORON represents another development of the above-mentioned compounds. It is a 
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Figure 1. Structure of EMICORON. 
Figure 1. Structure of EMICORON.
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This compound was synthesized for the first time in our laboratory in 2012 [6]. This first synthesis
of EMICORON was carried out through a linear synthesis that comprised five steps [6,7] (Figure 2).
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Figure 2. Schematic original protocol for the synthesis of EMICORON. Figure 2. Schematic original protocol for the synthesis of EMICORON.
High-Throughput 2018, 7, 22 3 of 6
The first step is the most important and involves the bromination of the
perylene-3,4:9,10-tetracarboxylic dianhydride to produce two regioisomers that are
dibromoderivates of the initial anhydride [7]. The regioselective synthesis of the desiderated
regioisomer—1,7-dibromo-3,4:9,10-tetracarboxylic dianhydride (Figure 2, compound 2a)—has been
performed by researchers [8] but without gaining any real advantage. In fact, in terms of yields
and atomic efficiency, it is still much more convenient to perform the bromination by following the
method reported by Franceschin and co-workers [7], which involves the separation of the obtained
regioisomers by classic column chromatography (CC) only after the last step of the synthesis protocol.
In spite of our various attempts, the yield of the synthesis obtained by this procedure has always been
found to be equal to around 28%.
EMICORON has shown to exhibit in vivo antitumor activity, with the compound being able to
reduce the growth of colon-rectal cancer in rats [9]. This result was demonstrated to be achieved
using a multi-target mechanism of action. At high doses, EMICRON acts as a telomerase inhibitor [6];
at minor concentrations, it induces apoptosis in tumor cells by rapidly triggering extensive damage to
telomeric DNA because of the displacement of the telomeric protein protection of telomeres 1 known
as POT1 [6].
EMICORON has also been shown to bind G-rich oncogene promoters and downregulate the
expression of genes [10]. Moreover, in both in vitro and in vivo studies, it has been observed that
EMICRON acts with other conventional antitumor drugs in a synergic effect [11].
Because of all these synthetic and pharmacological reasons, the main aim of this work was to
improve the total yield of the synthesis in order to get more amounts of EMICORON for further
preclinical studies.
2. Materials and Methods
2.1. Materials
All the reagents, anhydrous solvents, and deuterated solvents were purchased from Sigma-Aldrich
(Saint Louis, MO, USA) and used with no further purification.
Silica gel for classical column chromatography (40–63 µm particle size) was purchased from Fluka
Analytical (St. Gallen, Switzerland).
2.2. Instrumentation
1H-NMR spectra were recorded on a Varian (now Agilent Technologies) (Santa Clara, CA, USA)
Mercury 300 MHz spectrometer.
CDCl3 (deuteron-chloroform) was used as deuterated solvent, and the chemical shifts were
expressed from TMS (s, 0.00 ppm).
2.3. Synthesis
2.3.1. Synthesis of N,N′-bis[2-(1-piperidino)-ethyl]-1,7-dibromoperylene-3,4:9,10-tetracarboxylic
diimide (PIPER-Br)
Under argon atmosphere, 5.001 g of a mixture of the two isomers of
dibromoperylene-3,4:9,10-tetracarboxylic dianhydride in ratio 8:1 (w/w) were dissolved at
room temperature in 18 mL of anhydrous DMA and 18 mL of anhydrous dioxane. At this point,
2.6 mL of 1-(2-amminoetyl)-piperidine were added. The reaction mixture was stirred at 110 ◦C for 12 h.
After cooling, cold water (4 ◦C) was added. Then, 6.522 g of the final product—a mixture of the two
isomers in ratio 8:1 (w/w)—were obtained and isolated by filtration as a red solid. The yield was 93%.
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2.3.2. Synthesis of N,N′-bis[2-(1-piperidino)-ethyl]-1-(1-piperidinyl)-7-bromoperylene-3,4:9,10-
tetracarboxylic diimide (PIP-PIPER-Br)
Under argon atmosphere, 6.011 g of the products obtained from the previous reaction were
dissolved in 30 mL of piperidine and stirred at 80 ◦C for 30 min. Cold water at 4 ◦C was added, and the
crude product was extracted with dichloromethane. The organic phase was, then, washed with water
until the aqueous layer was neutralized. The product of interest—a mixture of the two isomers in
ratio 8:1 (w/w)—with a weight of 4.502 g and a yield of 71% was separated from the crude product by
means of column chromatography on silica gel using a mixture of dichloromethane and methanol 95:5
(v/v) as eluting system.
2.4. NMR Data of All the Synthetic Compounds
N,N′-bis[2-(1-piperidino)-ethyl]-1,7-dibromoperylene-3,4:9,10-tetracarboxylic diimide (Figure 2,
compound 3a): 1H-NMR (300 MHz, CDCl3) δ: 9.44 (2H, d, J = 8.1 Hz, aromatic H), 8.88 (2H, s, aromatic
H), 8.66 (2H, d, J = 8.1 Hz, aromatic H), 4.36 (4H, t, J = 7.0 Hz, Nimidic-CH2), 2.67 (4H, t, J = 7.0 Hz,
Npiperidine-CH2), 2.57–2.53 (8H, m, CH2piperidine), 1.62–1.54 (8H, m, CH2piperidine), 1.47–1.41 (4H, m,
CH2piperidine) (Spectrum reported in Supplementary Material as Figure S1).
N,N′-bis[2-(1-piperidino)-ethyl]-1-(1-piperidinyl)-7-bromoperylene-3,4:9,10-tetracarboxylic
diimide (PIP-PIPER-Br) (Figure 2, compound 4a): 1H-NMR (300 MHz, CDCl3) δ: 9.41–9.34 (2H,
m, aromatic H), 8.80 (1H, s, aromatic H), 8.57 (1H, d, J = 8.2 Hz, aromatic H), 8.49–8.46 (2H, m,
aromatic H), 4.40–4.34 (4H, m, Nimidic-CH2), 3.46–3.34 (2H, m, Car-Npiperidine-CH2), 3.03–2.95 (2H,
m, Car-Npiperidine-CH2), 2.71–2.55 (12H, m, Npiperidine-CH2 and CH2piperidine), 1.89–1.42 (18H, m,
CH2piperidine) (Spectrum reported in Supplementary Material as Figure S2).
3. Results and Discussions
The improvement in the synthesis of EMICORON was obtained by the modification of two
reactions corresponding to the second and the third steps in the original protocol [6,7].
The second step leads to the formation of N,N′-bis[2-(1-piperidino)-ethyl]-1,7-
dibromoperylene-3,4:9,10-tetracarboxylic diimide (PIPER-Br) (Figure 2, compound 3a). In this study,
the reaction time was increased from 6 to 12 h with respect to the previous protocol. Moreover,
the precipitation of the product was performed by adding cold water at 4 ◦C to the reaction mixture
instead of water at room temperature (Figure 3). This new methodology was able to improve the yield
of this reaction step by about 20%.
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The third step leads to the formation of PIP-PIPER-Br (N,N′-bis
[2-(1-piperidino)-ethyl]-1-(1-piperidinyl)-7-bromoperylene-3,4:9,10-tetracarboxylic diimide (Figure 2,
compound 4a). The original protocol involved the use of a mixture of dioxane and piperidine in
ratio 1:1 (v/v), together with hydroquinone at 100 ◦C, for 40 min. The presence of hydroquinone was
essential to promote the inhibition of some radical reactions that could happen in similar conditions,
leading to dehalogenated collateral products [12,13]. Moreover, it was not possible to isolate the final
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product of this step as pure compound in such conditions, and a further classical CC on silica gel was
necessary in order to also remove some reaction products of the hydroquinone.
By contrast, the new protocol proposed in this study proceeds by totally removing dioxane,
and using only piperidine, both as solvent and reagent, and under Argon atmosphere. In such
conditions, the reaction was observed to yield in less time and at a lower temperature (Figure 4).
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